This statement might surprise many but companies have extensive legal rights over the interactions with the PBS and its administration. They just generally choose not to exercise these rights.
The industry has many rights in decision-making, it just rarely exercises these rights
February 15, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech -
Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children
February 18, 2026 - - Latest News -
CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News -
Targeted blood cancer treatments proposed for funding in New Zealand
February 18, 2026 - - Latest News -
Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate
February 18, 2026 - - Australian Biotech

